Nevirapine versus efavirenz for patients co-infected with HIV and tuberculosis: A randomised non-inferiority trial

The Lancet Infectious Diseases

Volumn 13, Issue 4, 2013, Pages 303-312

  Bonnet, Maryline ^a   Bhatt, Nilesh ^b   Baudin, Elisabeth ^a   Silva, Carlota ^a   Michon, Christophe ^c   Taburet, Anne Marie ^d   Ciaffi, Laura ^e   Sobry, Agnès ^e   Bastos, Rui ^f   Nunes, Elizabete ^f   Rouzioux, Christine ^g   Jani, Ilesh ^b   Calmy, Alexandra ^e  

^a EPICENTRE   (France)

^b INSTITUTO NACIONAL DE SAÚDE   (Mozambique)

^c Regional Hospital   (France)

^d BICÊTRE HOSPITAL   (France)

^e GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^f MAPUTO CENTRAL HOSPITAL   (Mozambique)

^g UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; BILIRUBIN; COTRIMOXAZOLE; EFAVIRENZ; ETHAMBUTOL; ETHAMBUTOL PLUS ISONIAZID PLUS PYRAZINAMIDE PLUS RIFAMPICIN; ISONIAZID; LAMIVUDINE; LAMIVUDINE PLUS NEVIRAPINE PLUS STAVUDINE; LAMIVUDINE PLUS STAVUDINE; NEVIRAPINE; PYRAZINAMIDE; PYRIDOXINE; RIFAMPICIN; TENOFOVIR; TUBERCULOSTATIC AGENT; VIRUS RNA; ZIDOVUDINE;

ABDOMINAL TUBERCULOSIS; ABSCESS; ADULT; ALLERGIC REACTION; ANEMIA; ANTIVIRAL ACTIVITY; ANTIVIRAL THERAPY; ARTICLE; CD4 LYMPHOCYTE COUNT; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; DYSPNEA; EDEMA; FATIGUE; FEMALE; FOLLOW UP; GENOTYPE; HEADACHE; HEMOPTYSIS; HEPATITIS; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; LEUKOPENIA; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MILIARY TUBERCULOSIS; MIXED INFECTION; MOZAMBIQUE; MULTICENTER STUDY; NEUTROPENIA; OUTCOME ASSESSMENT; PATIENT COMPLIANCE; PATIENT COUNSELING; PATIENT EDUCATION; PRIORITY JOURNAL; PSYCHOSOCIAL CARE; RANDOMIZED CONTROLLED TRIAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RASH; SIDE EFFECT; STEVENS JOHNSON SYNDROME; SYSTEMATIC REVIEW; TUBERCULOSIS; TUBERCULOUS LYMPHADENITIS; TUBERCULOUS MENINGITIS; TUBERCULOUS OSTEOMYELITIS; TUBERCULOUS PERICARDITIS; TUBERCULOUS PLEURISY; VIRUS MUTATION;

EID: 84875593092     PISSN: 14733099     EISSN: 14744457     Source Type: Journal    
DOI: 10.1016/S1473-3099(13)70007-0     Document Type: Article

References (37)

1. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach 2010, WHO, World Health Organization, Geneva.
2. Manosuthi W, Sungkanuparph S, Thakkinstian A, et al. Plasma nevirapine levels and 24-week efficacy in HIV-infected patients receiving nevirapine-based highly active antiretroviral therapy with or without rifampicin. Clin Infect Dis 2006, 43:253-255.
3. Cohen K, van Cutsem G, Boulle A, et al. Effect of rifampicin-based antitubercular therapy on nevirapine plasma concentrations in South African adults with HIV-associated tuberculosis. J Antimicrob Chemother 2008, 61:389-393.
4. Cohen K, Grant A, Dandara C, et al. Effect of rifampicin-based antitubercular therapy and the cytochrome P450 2B6 516G>T polymorphism on efavirenz concentrations in adults in South Africa. Antivir Ther 2009, 14:687-695.
5. Gengiah TN, Holford NH, Botha JH, et al. The influence of tuberculosis treatment on efavirenz clearance in patients co-infected with HIV and tuberculosis. Eur J Clin Pharmacol 2012, 68:689-695.
6. Matteelli A, Saleri N, Villani P, et al. Reversible reduction of nevirapine plasma concentrations during rifampicin treatment in patients coinfected with HIV-1 and tuberculosis. J Acquir Immune Defic Syndr 2009, 52:64-69.
7. Scourfield A, Zheng J, Chinthapalli S, et al. Discontinuation of Atripla as first-line therapy in HIV-1 infected individuals. AIDS 2012, 26:1399-1401.
8. Ford N, Mofenson L, Kranzer K, et al. Safety of efavirenz in first-trimester of pregnancy: a systematic review and meta-analysis of outcomes from observational cohorts. AIDS 2010, 24:1461-1470.
9. Technical update on treatment optimization. Use of efvairenz during pregnancy: a public health perspective 2012, WHO, World Health Organization, Geneva.
10. Untangling the web: antiretroviral price reduction (accessed Sept 19, 2012). http://utw.msfaccess.org/.
11. Swaminathan S, Padmapriyadarsini C, Venkatesan P, et al. Efficacy and safety of once-daily nevirapine- or efavirenz-based antiretroviral therapy in HIV-associated tuberculosis: a randomized clinical trial. Clin Infect Dis 2011, 53:716-724.
12. Shipton LK, Wester CW, Stock S, et al. Safety and efficacy of nevirapine- and efavirenz-based antiretroviral treatment in adults treated for TB-HIV co-infection in Botswana. Int J Tuberc Lung Dis 2009, 13:360-366.
13. 2R Study. Clin Infect Dis 2009, 48:1752-1759.
14. Boulle A, van Cutsem G, Cohen K, et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008, 300:530-539.
15. Kwara A, Ramachandran G, Swaminathan S Dose adjustment of the non-nucleoside reverse transcriptase inhibitors during concurrent rifampicin-containing tuberculosis therapy: one size does not fit all. Expert Opin Drug Metab Toxicol 2010, 6:55-68.
16. Maartens G, Decloedt E, Cohen K Effectiveness and safety of antiretrovirals with rifampicin: crucial issues for high-burden countries. Antivir Ther 2009, 14:1039-1043.
17. Prequalification programme. A United Nations Programme managed by WHO WHO, (accessed Sept 19, 2012). http://www.who.int/prequal/.
18. Agence Française de recherche sur le sida et les hépatites virales. ANRS Scale To grade the severity of adverse events (accessed Sept 19, 2012). http://www.anrs.fr/Rubriques-transversales/Outils-pour-la-recherche.
19. Bonnet M, Bhatt NB, Jani IV, et al. Pharmacokinetics of nevirapine in tuberculosis-HIV co-infected patients receiving rifampicin ANRS12146 (CARINEMO). International AIDS Society Conference on HIV Pathogenesis, Treatment and Prevention; Cape Town, South Africa; July 19-22, 2009.
20. Treatment of tuberculosis: guidelines for national programs 2003, WHO, World Health Organization, Geneva. 3rd edn.
21. Meintjes G, Lawn SD, Scano F, et al. Tuberculosis-associated immune reconstitution inflammatory syndrome: case definitions for use in resource-limited settings. Lancet Infect Dis 2008, 8:516-523.
22. Medical dictionary for regulatory activities (accessed Sept 19, 2012). http://www.meddramsso.com.
23. van Leth F, Phanuphak P, Ruxrungtham K, et al. Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN study. Lancet 2004, 363:1253-1263.
24. Blackwelder WC "Proving the null hypothesis" in clinical trials. Control Clin Trials 1982, 3:345-353.
25. Mbuagbaw LC, Irlam JH, Spaulding A, Rutherford GW, Siegfried N Efavirenz or nevirapine in three-drug combination therapy with two nucleoside-reverse transcriptase inhibitors for initial treatment of HIV infection in antiretroviral-naive individuals. Cochrane Database Syst Rev 2010, 12. CD004246.
26. Soriano V, Arasteh K, Migrone H, et al. Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial. Antivir Ther 2011, 16:339-348.
27. Dejesus E, Mills A, Bhatti L, Conner C, Storfer S A randomised comparison of safety and efficacy of nevirapine vs. atazanavir/ritonavir combined with tenofovir/emtricitabine in treatment-naive patients. Int J Clin Pract 2011, 65:1240-1249.
28. Clumeck N, Mwamba C, Kabeya K, et al. First-line ART with lopinavir/ritonavir vs nevirapine with tenofovir/emtricitibine or zidovudine/lamivudine in a developing country: week 96 of a prospective randomized trial. Conference on Retroviruses and Opportunistic Infections; Seattle, WA, USA; March 5-8, 2012.
29. The effect of efavirenz versus nevirapine-containing regimens on immunologic, virologic and clinical outcomes in a prospective observational study. AIDS 2012, 26:1691-1705. HIV-CAUSAL Collaboration.
30. Tang MW, Kanki PJ, Shafer RW A review of the virological efficacy of the 4 World Health Organization-recommended tenofovir-containing regimens for initial HIV therapy. Clin Infect Dis 2012, 54:862-875.
31. Telenti A, Zanger UM Pharmacogenetics of anti-HIV drugs. Annu Rev Pharmacol Toxicol 2008, 48:227-256.
32. Dieterich DT, Robinson PA, Love J, Stern JO Drug-induced liver injury associated with the use of nonnucleoside reverse-transcriptase inhibitors. Clin Infect Dis 2004, 38(suppl 2):S80-S89.
33. Chen J, Mannargudi BM, Xu L, Uetrecht J Demonstration of the metabolic pathway responsible for nevirapine-induced skin rash. Chem Res Toxicol 2008, 21:1862-1870.
34. Flandre P Design of HIV non-inferiority trials: where are we going?. AIDS 2012, published online Oct 17. 10.1097/QAD.ob013e32835b105e.
35. Gulick RM, Ribaudo HJ, Shikuma CM, et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004, 350:1850-1861.
36. Davies G, Cerri S, Richeldi L Rifabutin for treating pulmonary tuberculosis. Cochrane Database Syst Rev 2007, 4. CD005159.
37. Avihingsanon A, Manosuthi W, Kantipong P, et al. Pharmacokinetics and 48-week efficacy of nevirapine: 400 mg versus 600 mg per day in HIV-tuberculosis coinfection receiving rifampicin. Antivir Ther 2008, 13:529-536.